Preliminary Translational Results from an Ongoing Phase 1 Study of Flotetuzumab, a CD123 x CD3 Dart®, in AML/MDS: Rationale for Combining Flotetuzumab and Anti-PD-1/PD-L1 ImmunotherapiesMichael P. Rettig, Jan Davidson‐Moncada, Hélène Lelièvre et al.|Blood|2017Cited by 12
Ruxolitinib in combination with prednisone and nilotinib exhibit synergistic effects in human cells lines and primary cells from myeloproliferative neoplasmsAlicia Arenas Cortés, Joaquín Martínez‐López, Rosa Ayala et al.|Haematologica|2018Cited by 9
Biomarker‑driven phase Ib clinical trial of OPB‑111077 in acute myeloid leukemiaJoaquín Martínez‐López, Juan Ballesteros, Pau Montesinos et al.|Medicine International|2022Cited by 4
High Throughput Screening, With a Flow Cytometry Automated Platform (Ex vivo Biotech), To Identify Potential Combination Partners, For The JAK 2 Inhibitor RuxolitinibAlicia Arenas, Joaquín Martínez‐López, Pilar Hernández-Campo et al.|Blood|2013Cited by 2
Ruxolitinib in Combination with Nilotinib and Prednisolone, a New Synergistic Approach to Treat MyelofibrosisAlicia Arenas, Joaquín Martínez‐López, Pilar Hernández-Campo et al.|Blood|2014Cited by 1